A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 26 Jan 2019
At a glance
- Drugs Naloxegol (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 18 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.